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Abstract 
Background and aims:  To assess the association of circulating calprotectin, an inflammation-
associated protein, with cardiovascular disease (CVD) risk and determine whether it improves 
risk prediction.  
Methods: Plasma calprotectin measurements were made at baseline in 5290 participants in the 
PREVEND prospective study. Hazard ratios (95% confidence intervals [CI]) for CVD were 
calculated.  
Results: After a median follow-up of 8.3 years, 339 first CVD events were recorded. Calprotectin 
concentration was correlated with several conventional risk factors as well as with high-
sensitivity C-reactive protein (hsCRP) (r=0.42). Calprotectin was log-linearly associated with 
CVD risk. The risk for CVD adjusted for conventional cardiovascular risk factors was 1.26 (95% 
CI, 1.13-1.41) per 1 standard deviation higher baseline loge calprotectin, and was 1.24 (95% CI, 
1.11-1.39) following further adjustment for triglycerides, body mass index, and other potential 
confounders. The association remained present after further adjustment for hsCRP 1.15 (95% 
CI, 1.02-1.30).  Comparing extreme quartiles of plasma calprotectin levels, the corresponding 
adjusted HRs for CVD were 1.96 (1.37-2.82), 1.89 (1.31-2.72), and 1.56 (1.07-2.29). The 
association of calprotectin with CVD risk did not vary importantly in several relevant clinical 
subgroups. Adding calprotectin to the Framingham CVD Risk Score was associated with a C-
index change (0.0016; p=0.42), difference in -2 log likelihood (p=0.038), IDI (0.0080; p<0.001), 
and NRI (4.03%; p=0.024). 
Conclusions: There is a log-linear association of calprotectin concentration with risk of CVD, 
which may be partly dependent on hsCRP. Adding calprotectin to conventional risk factors 
improves CVD risk assessment using measures of reclassification and -2 log likelihood. 
 
Keywords: calprotectin; cardiovascular disease; risk factor; risk prediction; cohort study 
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1. Introduction 
Though established risk factors such as a history of diabetes, blood pressure, blood lipids, and 
smoking status explain a large proportion of the risk of vascular disease,1 its pathogenesis is still 
not fully understood as it appears other additional factors may be involved. Accumulating 
evidence suggests that inflammatory processes may play an important role in the pathogenesis 
of coronary heart disease (CHD), which is the major manifestation of cardiovascular disease 
(CVD).2,3  The development of atherosclerosis is characterised by a chronic, low-grade 
inflammatory process.4 As a result, there has been an increasing interest in investigating the 
role of several inflammatory markers in CVD development. Several epidemiological studies 
have reported on the associations of both “downstream” (e.g. C-reactive protein, fibrinogen) and 
“upstream” (e.g. interleukins, tumor necrosis factor-α) markers with risk of CVD.5-7 Calprotectin, 
also known as S100A8/A9 complex or myeloid-related protein-8/14, is an inflammatory myeloid-
related protein that is mainly secreted by neutrophils.8  
 
Calprotectin is considered as an acute phase protein and elevated levels have been reported in 
several chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus 
erythematosus, cystic fibrosis, psoriasis, and inflammatory bowel diseases.9-11 In addition to its 
role in the modulation of inflammation, leukocyte trafficking, apoptosis, and immune response; 
calprotectin is used as a reliable marker for the diagnosis and follow-up of inflammatory bowel 
diseases.12,13 Emerging evidence suggests that calprotectin may be implicated in the 
pathogenesis of CVD. A number of studies have demonstrated elevated levels of calprotectin in 
patients with acute coronary syndromes (ACS), both at the site of coronary occlusion and in the 
systemic circulation, as well as in atherosclerotic plaques.14-17 However, because the evidence 
from these previous studies were based on cross-sectional evaluations, the temporal nature of 
the relationship between circulating calprotectin and CVD is not certain. A limited number of 
population-based prospective studies have reported associations between increased levels of 
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calprotectin and increased risk of cardiovascular events. These previous reports however, were 
either not sufficiently powered, did not account adequately for potential confounders, or were 
conducted in selected populations with pre-existing CVD.15,18,19 In addition, these previous 
studies did not assess the nature of the dose-response relationship between circulating 
calprotectin and CVD risk and did not evaluate whether the association is modified by relevant 
clinical characteristics. Given the uncertainties in the previous literature, we aimed to investigate 
in greater detail than ever before, the shape, nature, and magnitude of the prospective 
association between plasma calprotectin and risk of future CVD events using a population-
based cohort of 5290 participants free from pre-existing CVD at baseline. We also assessed the 
consistency of the association in important clinical subgroups and investigated the extent to 
which calprotectin concentrations could improve the prediction of first-onset CVD when added to 
a conventional CVD risk prediction model.  
 
2. Methods 
2.1. Study design and population  
The STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) 
guidelines for reporting observational studies in epidemiology was used to conduct the current 
study (Appendix 1).20 The present analyses employed the Prevention of Renal and Vascular 
End-stage Disease (PREVEND) study, a prospective cohort study based in a general population 
and which was designed to evaluate the natural course of urinary albumin excretion and its 
associations with renal disease and CVD. The selection of the cohort, study design, and 
recruitment methods have been described in previous reports.21-25 In brief, the PREVEND cohort 
study is based on a representative sample of men and women living in the city of Groningen 
located in the Netherlands. The cohort used for this analysis comprised of 6894 individuals aged 
32-80 years who were invited for the second screening phase of the PREVEND study and had 
their baseline assessments performed between 2001 and 2003. For the current analysis, we 
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used data of participants without pre-existing CVD, renal disease, or malignancy, which left a 
cohort of 5290 participants without missing information on plasma calprotectin, relevant 
confounders, and incident outcomes. The local ethics committee of the University Medical 
Center Groningen approved the PREVEND study protocol. Study procedures were conducted 
according to the Declaration of Helsinki and all participants provided written informed consent.  
 
2.2. Assessment of calprotectin and risk markers 
Study participants attended two outpatient visits during which baseline data were collected on 
sociodemographic characteristics, anthropometric measurements, medical history, and 
medication use. Additional information on medication use was collected from registries of all 
community pharmacies in the city of Groningen. This data source covers up-to-date information 
on medication use in 95% of PREVEND study participants.26 Fasting plasma and serum venous 
samples were taken from participants after 15 minutes of rest prior to sample collection. Plasma 
samples were prepared by centrifugation at 4 ºC and sera were stored at -80 ºC until 
measurements were done. Plasma calprotectin levels were measured using Gentian 
Calprotectin turbidimetric immunoassay (Gentian, Moss, Norway) applied on a Mindray BS-400 
analyser (Mindray, Shenzhen, China). HDL-C was measured by a homogeneous method (direct 
HDL, Aeroset System; Abbott Laboratories, Abbott Park, Illinois). Standard protocols were used 
to measure concentrations of total cholesterol, triglycerides, high sensitivity C-reactive protein 
(hsCRP), serum creatinine, and serum cystatin C and these have been described in previous 
reports.27-29 Fasting plasma glucose (FPG) was measured using dry chemistry (Eastman Kodak, 
Rochester, New York). Estimated glomerular filtration rate (eGFR) was estimated using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) combined creatinine-cystatin C 
equation.30 Body mass index (BMI) was calculated as the ratio of the weight in kilograms to the 
square of height in meters.  
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2.3. Outcome ascertainment 
The primary outcome for this analysis was first-onset composite CVD. Secondary outcomes 
were incident CHD and stroke events. We included all outcome events that occurred from study 
entry (2001-2003) to 1-1-2011. The source of data on hospitalization for incident CVD events 
was obtained from PRISMANT, which is the Dutch National Registry of hospital discharge 
diagnoses.31 Cardiovascular deaths and their dates were ascertained by data linkage with the 
Dutch Central Bureau of Statistics. Outcome data were coded according to the International 
Classification of Diseases, Ninth Revision (ICD-9) until 01 January 2009 and after this date, 
ICD-10 codes were used. First-onset composite CVD was defined as the combined outcomes of 
acute and subacute ischemic heart disease (IHD), acute myocardial infarction (AMI), coronary 
artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA), 
occlusion or stenosis of the precerebral or cerebral arteries, subarachnoid hemorrhage, 
intracerebral hemorrhage, other intracranial hemorrhage, and other vascular interventions such 
as percutaneous transluminal angioplasty or bypass grafting of peripheral vessels and aorta. 
Coronary heart disease was defined as fatal or nonfatal IHD, fatal or nonfatal MI, CABG, and 
PTCA. Stroke events were defined as occlusion and stenosis of precerebral or cerebral arteries, 
and carotid obstruction, subarachnoid hemorrhage, intracerebral hemorrhage, other and 
unspecified intracranial hemorrhage. 
 
2.4. Statistical analyses 
Skewed variables which included calprotectin were natural log transformed to achieve 
approximately normal distributions. Baseline characteristics were presented as means (standard 
deviation, SD) or median (interquartile range, IQR) for continuous variables and percentages for 
categorical variables. Age- and sex-adjusted partial correlation coefficients were estimated to 
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assess the cross-sectional correlations of plasma calprotectin levels with CVD risk markers. 
Time-to-event Cox proportional hazard regression models were used to compute hazard ratios 
(HRs) for the associations of plasma calprotectin with risk of cardiovascular outcomes, after 
confirmation of no major departure from the proportionality of hazards assumptions.32 
Cumulative Kaplan-Meier curves for CVD during follow-up were plotted according to quartiles of 
calprotectin. The shape of the relationship between plasma calprotectin and CVD risk was 
characterized by plotting HRs estimated within quartiles of baseline calprotectin relative to the 
bottom quartile versus the mean calprotectin value in each quartile using floating absolute risks 
(FARs).33 Given the approximately linear shape of the calprotectin-CVD association, HRs were 
computed per 1 SD higher loge calprotectin concentration. The SD of baseline loge calprotectin 
level was 0.54 (equivalent to approximately 2-fold higher circulating calprotectin level, as 
e0.54=1.72). We also modelled HRs as quartiles defined according to the baseline distribution of 
plasma calprotectin levels. The following four models were used for adjustment: (i) age and sex; 
(ii) other established CVD risk factors (history of diabetes mellitus, smoking status, SBP, total 
cholesterol, and HDL-C); (iii) other potential confounders (triglycerides, BMI, alcohol 
consumption, FPG, and eGFR); and (iv) hsCRP. We used interaction tests to assess statistical 
evidence of effect modification by several clinical characteristics. To minimize the possibility of 
bias due to reverse causation, we performed sensitivity analyses that excluded the first two 
years of follow-up, participants with a history of diabetes mellitus at baseline, or participants on 
lipid-lowering medication.  
 
Finally, we assessed whether adding information on plasma calprotectin to conventional 
cardiovascular risk factors34 is associated with an improvement in CVD risk prediction. To 
achieve this, we calculated measures of discrimination for censored time-to-event data (Harrell’s 
C-index 35) and reclassification. To investigate the change in C-index on addition of calprotectin 
to conventional cardiovascular risk factors, two CVD risk prediction models were fitted; one 
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based on conventional risk factors included in the Framingham CVD Risk Score (FRS) (i.e., 
age, sex, smoking status, SBP, total cholesterol, and HDL-C)36 and the second model with the 
FRS risk factors plus calprotectin. We then evaluated whether calprotectin helps to correctly 
classify participants into predicted CVD risk categories. Using the American College of 
Cardiology (ACC) and American Heart Association (AHA) 2013 cardiovascular risk categories of 
low (<5%), intermediate (5 to <7.5%), and high (≥7.5%) risk,37 reclassification was assessed 
using the categorical net-reclassification-improvement (NRI).38 Reclassification analysis was 
based on the nine years of follow-time for this study. Finally, we calculated the integrated 
discrimination improvement (IDI), which integrates the NRI over all possible cutoffs of predicted 
risk and mathematically corresponds to the difference in discrimination slopes of the 2 models in 
comparison.38 Our risk prediction analysis was restricted to study participants without known 
histories of CVD or diabetes mellitus at baseline. Given that Harrell’s C-index is based on ranks 
rather than on continuous data, it can be insensitive in detecting differences.39,40 To avoid 
discarding potential biomarkers that can be used in risk prediction, sensitive risk discrimination 
methods such as the -2 log likelihood test have been recommended.39,40  Therefore, in addition 
to Harrel’s C-index, we tested for differences in the -2 log likelihood of prediction models with 
and without inclusion of calprotectin. We conducted all statistical analyses using Stata version 
14 (Stata Corp, College Station, Texas). 
 
3. Results 
3.1. Baseline characteristics 
The mean age at study entry of participants was 53 (SD 12) years and 47.8% were men (Table 
1). There were significant differences in baseline characteristics (including calprotectin levels) 
between participants who did and did not develop CVD. The overall median (IQR) plasma 
concentration of calprotectin was 0.50 (0.35-0.70) mg/L. Calprotectin concentration was weakly 
correlated with several risk markers: positively with age, BMI, blood pressure, total cholesterol, 
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triglycerides, and FPG; and inversely with HDL-C. The strongest correlation was observed with 
hsCRP (r=0.42). Baseline calprotectin concentrations were higher by 9% in males compared 
with females and by 22% in current smokers compared with never and former smokers (Table 
2).  
 
3.2. Plasma calprotectin and risk of incident CVD 
During a median follow-up of 8.3 (IQR, 7.7-8.9) years, 339 incident CVD events (annual rate 
8.22/1,000 person-years at risk; 95% CI: 7.39 to 9.14) occurred. Cumulative hazard curves 
showed an increased risk of CVD in the top quartile of calprotectin levels compared with the 
bottom three quartiles (p-value for log-rank test < 0.001 for all; Figure 1). In analyses adjusted 
for age and sex and also for conventional risk factors, there was a log-linear association of 
calprotectin with risk of CVD (Figure 2). Table 3 reports the associations of plasma calprotectin 
with the risk of CVD outcomes. The age- and sex-adjusted HR (95% CI) of CVD per 1 SD 
increase in baseline loge calprotectin was 1.38 (1.25 to 1.54) and it was 1.26 (1.13 to 1.41) 
following further adjustment for history of diabetes, smoking status, SBP, total cholesterol, and 
HDL-C. The association remained consistent on additional adjustment for triglycerides, BMI, 
alcohol consumption, FPG, and eGFR, but was somewhat attenuated by further adjustment for 
loge hsCRP 1.15 (1.02 to 1.30). In analyses that compared the highest with the lowest quartiles 
of the distribution of calprotectin concentrations, the corresponding adjusted HRs for the 
respective models were 2.60 (1.82 to 3.71), 1.96 (1.37 to 2.82), and 1.56 (1.07 to 2.29). The 
findings were broadly similar in sub-analyses of CHD; however, the association was less robust 
for stroke and in subsidiary analyses using ischemic stroke as a specific endpoint (Table 3). In 
sensitivity analyses that excluded the first two years of follow-up, people with diabetes mellitus 
at baseline, or people on lipid-lowering medication, the findings were qualitatively similar 
(Appendix 2). The HRs for CVD did not vary importantly by age, sex, alcohol consumption, 
smoking status, BMI, blood pressure, cholesterol, eGFR, or hsCRP; except for evidence of 
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effect modification by FPG (P=0.032) (Appendix 3). The HR was more extreme in participants 
with high levels of FPG (≥ 5.0 mmol/l) compared to those with lower levels (< 5.0 mmol/l). To put 
the strength of the association of calprotectin levels with CVD risk into context, direct 
comparisons were made to associations of several established and emerging CVD risk markers. 
The association of circulating calprotectin with CVD risk was of comparable strength to SBP, 
total cholesterol, and hsCRP (Appendix 4). 
 
3.3. Plasma calprotectin and CVD risk prediction 
A CVD risk prediction model (FRS) containing established cardiovascular risk factors yielded a 
C-index of 0.8105 (95% CI: 0.7906 to 0.8305). After addition of information on calprotectin 
levels, the C-index was 0.8121 (0.7920 to 0.8322), representing a non-significant increase of 
0.0016 (-0.0023 to 0.0055; p=0.42). However, when investigating differences in the -2 log 
likelihood of the FRS, the -2 log likelihood was significantly improved on addition of calprotectin 
to the FRS (p for comparison=0.038). Of the 1071 participants who remained free of CVD, 49 
(4.58%) were correctly reclassified to a lower risk category and 28 (2.61%) were reclassified to 
a higher risk category. Of the 338 participants who developed CVD, 18 (5.33%) were correctly 
reclassified to a higher risk category and 11 (3.25%) were reclassified to a lower risk category. 
After taking into account inappropriate reclassification, there was a significant improvement in 
the classification of participants into predicted CVD risk categories (NRI: 4.03%, 0.52 to 7.54%; 
p=0.024). The IDI was 0.0080 (95% CI, 0.0044 to 0.0116; p<0.001).  
 
4. Discussion 
4.1. Main findings 
In this large-scale population-based study of individuals without a history of CVD at study entry, 
baseline calprotectin levels were weakly and positively correlated with indices of adiposity, as 
well as lipid, metabolic, and renal function markers. A moderately strong correlation was 
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observed with hsCRP. The current analysis of 5290 individuals has demonstrated a log-linear 
association of calprotectin concentration with the risk of CVD. The initial association changed 
very little after adjustment for established and other emerging risk factors, suggesting that 
calprotectin levels are independent of such factors. However, the association was somewhat 
attenuated when further adjusted for inflammation as measured by hsCRP. We showed that 
HRs for CVD with calprotectin levels were similar in a range of clinically relevant subgroups, 
such as in men and women, or at different levels of established risk factors, except for evidence 
of effect modification by FPG. The associations were also similar in several sensitivity analyses. 
In investigation of other CVD endpoints, although the findings were broadly similar for CHD, that 
for composite and ischemic stroke events were less distinct or robust and which could be 
attributed to the low event rates. In direct comparisons with several established and emerging 
cardiovascular markers, we showed that the HR for CVD with calprotectin levels may be 
comparable to some of these markers. Finally, adding calprotectin to the FRS did not improve 
discrimination of CVD risk using Harrell’s C-index; but there was a significant improvement on 
using the -2 log likelihood method. There was also significant improvement in reclassification of 
participants across clinical risk categories 
 
4.2. Comparison with previous work 
In a prospective, nested case-control validation study consisting of 255 case-control pairs 
among healthy postmenopausal women followed for a median time of 2.9 years, Healy and 
colleagues demonstrated an increased risk of cardiovascular events (nonfatal myocardial 
infarction or stroke, or cardiovascular death) with increased levels of calprotectin and this was 
independent of conventional risk factors as well as CRP.15 In another nested case-control study 
of patients with ACS, the risk of cardiovascular death or myocardial infarction after 30 days 
increased with increased levels of calprotectin.18 In a more recent cohort consisting of 664 
middle-aged individuals, Cotoi reported independent associations of calprotectin with coronary 
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events and CVD death; however, the associations were more robust in women.19 Drawbacks of 
some of these previous studies included (i) small sample sizes; (ii) short-term follow-up periods; 
(iii) inclusion of participants with pre-existing CVD; (iv) the inability to account for a 
comprehensive panel of other potential confounders; (v) no formal assessment of the shape of 
the relationship between plasma calprotectin and CVD risk was undertaken; hence it is not 
known if there is a dose-response relationship to the association; (vi) no subgroup analysis was 
undertaken to assess if the association is modified by relevant clinical characteristics; or (vii) no 
formal risk prediction analyses was performed. Though the general findings concur with these 
previous studies; to the best of our knowledge, a comprehensive assessment of the 
independence, magnitude, shape, and consistency of the prospective association between 
plasma calprotectin and risk of CVD in the general population has not been previously reported. 
Our findings show that the association between plasma calprotectin and increased CVD risk is 
consistent with a log-linear shape. Furthermore, the association is independent of several 
conventional risk factors as well as alcohol consumption and renal function, but was 
considerably attenuated but not abrogated by hsCRP. The association was also similar in 
important subgroups, such as men and women; which are contrary to findings suggesting that 
the relationship may only be important in women.19 The null findings we observed for stroke is 
also consistent with that of a previous study.19 Finally, the current study reported estimates of 
the metrics for risk discrimination and reclassification for the first time.   
 
4.3. Possible explanations for findings  
Findings from a number of studies have implicated calprotectin in the pathogenesis of 
CHD.14,15,17  Calprotectin is an inflammation-associated protein and given that inflammation 
plays a major role in the pathogenesis of atherosclerosis41 and with coronary atherosclerosis 
being a precursor for most coronary events; calprotectin may be involved in the pathogenesis of 
CHD via inflammatory processes. Our results show that the association of calprotectin with 
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CVD/CHD was considerably attenuated on adjusting for hsCRP (an inflammatory biomarker, 
which is also a strong independent predictor of CHD/CVD5); findings which substantiate the 
importance of hsCRP as a confounding factor and lend further support to the inflammation 
hypothesis of CVD/CHD development. Calprotectin is highly expressed or the most abundant 
cytosolic protein in neutrophils,8  which are involved in the pathophysiology of coronary 
syndromes.42,43 Since neutrophils are strongest independent determinants of calprotectin,19 it 
has been suggested that calprotectin may be a marker of neutrophil involvement in CVD 
pathogenesis.19 Evidence from clinical studies in humans and animal models suggest that 
neutrophils may play important roles in atherogenesis and as mediators of plaque 
destabilization44-46 via endothelial activation, oxidative stress as a result of generation of reactive 
oxygen species, low-density lipoprotein oxidation, and apoptosis.45-47 Morrow and colleagues 
also suggest that calprotectin may not only be a marker of neutrophil activation, but also be 
directly involved in CVD/CHD pathogenesis via inflammatory and thrombotic responses.18 
Indeed, data from animal models suggest calprotectin (i) is essential for neutrophil recruitment 
at sites of injury48 and (ii) binds to receptor for advanced glycation end-products (RAGE), which 
trigger inflammatory and thrombotic responses49 or stimulate the production of neutrophils and 
inflammatory monocytes, leading to impaired regression of atherosclerotic plaques.50 The 
absence of calprotectin in hyperlipidemic mice has also been shown to be associated with 
delayed atherosclerosis.51 In human studies, calprotectin has been shown to activate the 
vascular endothelium, impair endothelial integrity,52,53 and is also strongly correlated with pro-
inflammatory cytokines (such as interferons, interleukins, tumor necrosis factor-α),19 which are 
proatherogenic and play important roles in CVD development.44 The mechanistic evidence is 
still early and further studies are required to investigate any mediating effects of calprotectin on 
atherosclerosis and CVD development. 
 
4.4 Implications of findings 
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The current findings of a log-linear, independent, and specific association of calprotectin 
concentration with CVD, may suggest the existence of a causal relationship; and the added 
prognostic value of calprotectin on top of established risk factors may have several implications 
for the development of CVD prevention strategies. However, further studies are needed to 
replicate these findings, and which will stimulate further study to help determine if calprotectin is 
causally involved in CVD/CHD development and whether information on calprotectin might aid 
in the early identification of people at high risk of future CVD. The findings also suggest that 
calprotectin might be involved in inflammatory processes that underlie CVD development and 
could be a potential new therapeutic target that can be exploited to complement lipid-lowering 
strategies. Indeed, findings from a previous study suggest that intensive statin therapy lowers 
levels of calprotectin by day 30.18 Drugs that block the binding of calprotectin to its receptors 
have already been developed and approved for human clinical testing,54,55 opening up new 
opportunities for CVD prevention.  
 
4.5. Strengths and limitations 
Strengths and potential limitations of the current study merit careful consideration. These new 
data involve many more participants and incident CVD cases than the previous studies 
conducted in general population settings.15,19 Participants were identified from population 
registers; follow-up was long; there was minimization of potential biases by exclusion of 
individuals with prevalent CVD; concomitant measurements of several established and 
emerging risk factors enabled adjustment for a range of possible confounding factors; and the 
analysis was comprehensive which included assessment of the dose-response relationship, 
evaluation of effect modification, conducting formal risk prediction analyses using sensitive 
measures such as the -2 log likelihood, and testing the robustness of the findings using several 
sensitivity analyses. Limitations of the current study included (i) absence of data on neutrophil 
counts which precluded the ability to assess if the calprotectin-CVD association is independent 
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of or modified by neutrophil count; (ii) the inability to correct for regression dilution because of 
absence of repeat measurements, which could have underestimated the associations 
demonstrated; (iii) though the study had complete measurements of risk factors used in 
standard risk prediction algorithms and prevalent CVD or diabetes were excluded at baseline, 
participants were not adequately suitable for risk prediction and reclassification analyses as no 
participant was followed up for 10 years; (iv) the risk reclassification metrics (e.g., NRI) used 
have inherent limitations, such as dependence on the choice of cutoff and time frame for 
predicted risks and on the age distribution of the study population; (v) the potential for residual 
confounding due to other unmeasured covariates; and (vi) inability to generalize the findings to 
different ethnicities.  
 
 
 
5. Conclusion 
In a predominantly Caucasian population, there is a log-linear association of calprotectin 
concentration with risk of CVD, which is independent of established risk factors but may be 
partly dependent on inflammation as measured by hsCRP. Furthermore, adding calprotectin to 
conventional risk factors improves CVD risk assessment using measures of reclassification 
and -2 log likelihood. Further assessment of the role of calprotectin in CVD prevention is 
warranted.  
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Figure Legends 
 
Figure 1. Cumulative Kaplan-Meier curves for cardiovascular disease during follow-up 
according to quartiles of calprotectin 
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Figure 2. Hazard ratios for incident cardiovascular disease, by baseline concentrations of 
plasma calprotectin using floating absolute risks 
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A, Hazard ratios were adjusted for age and sex; B, adjustment in A plus smoking status, history 
of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
 
 24 
 
Table 1. Baseline participant characteristics overall and according to cardiovascular 
disease development 
 Overall  
(N=5290) 
Mean (SD) or 
median (IQR) or n 
(%) 
Without CVD 
(N=4951) 
Mean (SD) median 
(IQR) or n (%) 
With CVD  
(N=339) 
Mean (SD) or 
median (IQR) or n 
(%) 
p-value 
     
Plasma calprotectin (mg/L) 0.50 (0.35-0.70) 0.49 (0.35-0.69) 0.60 (0.44-0.85) < 0.001 
     
Questionnaire     
Male 2530 (47.8) 2288 (46.2) 242 (71.4) < 0.001 
Age at survey (years) 53 (12) 52 (12) 63 (11) < 0.001 
History of diabetes 282 (5.3) 240 (4.9) 42 (12.4) < 0.001 
Current smokers 1456 (27.5) 1345 (27.2) 111 (32.7) < 0.001 
Alcohol consumers 4001 (75.6) 3768 (76.1) 233 (68.7) 0.002 
Use of anti-hypertensive 
medication 
770 (15.5) 657 (14.2) 113 (34.4) < 0.001 
Use of lipid-lowering medication 126 (2.9) 105 (2.6) 21 (7.0) < 0.001 
     
Physical measurements     
BMI (kg/m2) 26.5 (4.3) 26.4 (4.3) 27.7 (3.9) < 0.001 
SBP (mmHg) 126 (18) 125 (18) 140 (20) < 0.001 
DBP (mmHg) 73 (9) 73 (9) 79 (9) < 0.001 
     
Lipid markers     
Total cholesterol (mmol/l) 5.47 (1.04) 5.45 (1.04) 5.77 (1.10) < 0.001 
HDL-C (mmol/l) 1.27 (0.31) 1.28 (0.31) 1.16 (0.29) < 0.001 
Triglycerides (mmol/l) 1.11 (0.80-1.59) 1.09 (0.79-1.57) 1.33 (0.98-1.87) < 0.001 
     
Metabolic, inflammatory, and 
renal function markers 
    
hsCRP (mg/l) 1.30 (0.61-2.89) 1.25 (0.59-2.79) 2.22 (1.04-4.73) < 0.001 
Fasting plasma glucose (mmol/l) 5.00 (1.10) 4.97 (1.07) 5.38 (1.42) <0.001 
Creatinine (µmol/l) 71.0 (62.0-80.0) 70.5 (62.0-79.0) 76.0 (67.0-89.0) < 0.001 
Cystatin C (mg/dl) 0.90 (0.20) 0.89 (0.18) 1.04 (0.34) < 0.001 
eGFR (ml/min/1.73 m2) 92.7 (16.7) 93.5 (16.2) 80.8 (19.1) < 0.001 
 
Continuous variables are reported as mean ± SD or median (interquartile range) and categorical variables 
are reported as n (%); BMI, body mass index;  DBP, diastolic blood pressure; eGFR, estimated 
glomerular filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration  
combined creatinine-cystatin C equation); HDL-C, high-density lipoprotein cholesterol; hsCRP, high 
sensitivity C-reactive protein; IQR, interquartile range;  SBP, systolic blood pressure; SD, standard 
deviation. 
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Table 2. Cross-sectional Correlates of Plasma Calprotectin 
 
 
Partial correlation 
r (95% CI)a 
Percentage difference (95% CI) in 
calprotectin levels per 1 SD higher or 
compared to reference category of 
correlateb 
   
Loge calprotectin (mg/L) - - 
   
Sex   
    Female - Ref 
    Male - 9% (6, 13)** 
   
Questionnaire   
Age at survey (years) 0.11 (0.09, 0.14)*** 6% (5, 8)*** 
History of diabetes   
    No - Ref 
    Yes - 9% (2, 17) 
Smoking status   
    Never and former smokers - Ref 
    Current smokers - 22% (18, 26)*** 
Alcohol consumption   
    Non-consumers - Ref 
    Current consumers - -7% (-10, -4)*** 
Use of anti-hypertensive medication   
    No - Ref 
    Yes - 11% (6, 16)*** 
Use of lipid-lowering medication   
    No  Ref 
    Yes  9% (-1, 19) 
   
Physical measurements   
BMI (kg/m2) 0.17 (0.14, 0.19)*** 9% (8, 11)*** 
SBP (mmHg) 0.14 (0.11, 0.16)*** 9% (7, 11)*** 
DBP (mmHg) 0.10 (0.08, 0.13)*** 6% (5, 8)*** 
   
Lipid markers   
Total cholesterol (mmol/l) 0.08 (0.06, 0.11)*** 5% (3, 6)*** 
HDL-C (mmol/l) -0.15 (-0.18, -0.13)*** -9% (-10, -7)*** 
Triglycerides (mmol/l) 0.10 (0.07, 0.13)*** 6% (4, 7)*** 
   
Metabolic, inflammatory, and renal function 
markers 
  
hsCRP (mg/l) 0.42 (0.40, 0.44)*** 26% (24, 27)*** 
Fasting plasma glucose (mmol/l) 0.05 (0.02, 0.08)*** 3% (1, 4)** 
Creatinine (µmol/l) 0.02 (-0.01, 0.05) 1% (-0, 3) 
Cystatin C (mg/dl) 0.13 (0.11, 0.16)*** 8% (7, 10)*** 
eGFR (ml/min/1.73 m2) -0.11 (-0.14, -0.09)*** -8% (-9, -6)*** 
BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate (as calculated using 
the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation); HDL-C, high-
density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; Ref, reference; SD, standard deviation; 
SBP, systolic blood pressure; 
Asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001; a, Partial correlation coefficients loge 
between calprotectin and the row variables; b, Percentage change in loge calprotectin levels per 1 SD increase in the row variable 
(or for categorical variables, the percentage difference in mean loge calprotectin levels for the category versus the reference) 
adjusted for age and sex. 
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Table 3. Prospective Associations of Plasma Calprotectin With Risk of Cardiovascular Disease 
Calprotectin Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Cardiovascular disease 
Per 1 SD increase 339 / 5290 1.38 (1.25 to 1.54) < 0.001 1.26 (1.13 to 1.41) < 0.001 1.24 (1.11 to 1.39) < 0.001 1.15 (1.02 to 1.30) 0.027 
Quartile 1 (0.02-0.35) 41 / 1333 ref  ref  ref  ref  
Quartile 2 (0.36-0.50) 79 / 1382 1.74 (1.19 to 2.54) 0.004 1.53 (1.05 to 2.24) 0.028 1.51 (1.03 to 2.20) 0.034 1.41 (0.96 to 2.07) 0.076 
Quartile 3 (0.51-0.70) 97 / 1308 1.99 (1.38 to 2.88) < 0.001 1.70 (1.17 to 2.45) 0.005 1.67 (1.15 to 2.41) 0.007 1.52 (1.05 to 2.21) 0.028 
Quartile 4 (0.71-13.23) 122 / 1277 2.60 (1.82 to 3.71) < 0.001 1.96 (1.37 to 2.82) < 0.001 1.89 (1.31 to 2.72) 0.001 1.56 (1.07 to 2.29) 0.022 
p-value for trend   < 0.001  < 0.001  < 0.001  0.037 
Coronary heart disease 
Per 1 SD increase 246 / 5290 1.38 (1.22 to 1.56) < 0.001 1.23 (1.08 to 1.41) 0.002 1.21 (1.06 to 1.38) 0.005 1.19 (1.03 to 1.38) 0.020 
Quartile 1 (0.02-0.35) 29 / 1323 ref  ref  ref  ref  
Quartile 2 (0.36-0.50) 53 / 1382 1.65 (1.05 to 2.60) 0.031 1.41 (0.90 to 2.23) 0.136 1.40 (0.88 to 2.21) 0.151 1.37 (0.87 to 2.17) 0.177 
Quartile 3 (0.51-0.70) 77 / 1308 2.28 (1.48 to 3.51) < 0.001 1.89 (1.22 to 2.91) 0.004 1.84 (1.19 to 2.85) 0.006 1.79 (1.16 to 2.78) 0.009 
Quartile 4 (0.71-13.23) 87 / 1277 2.62 (1.72 to 4.01) < 0.001 1.91 (1.24 to 2.94) 0.003 1.83 (1.18 to 2.82) 0.007 1.73 (1.09 to 2.73) 0.019 
p-value for trend   < 0.001  0.002  0.004  0.013 
    Stroke      
Per 1 SD increase 91 / 5290 1.25 (1.02 to 1.54) 0.035 1.19 (0.96 to 1.48) 0.117 1.17 (0.94 to 1.45) 0.173 0.96 (0.75 to 1.21) 0.710 
Quartile 1 (0.02-0.35) 13 / 1323 ref  ref  ref  ref  
Quartile 2 (0.36-0.50) 26 / 1382 1.81 (0.93 to 3.53) 0.082 1.69 (0.86 to 3.31) 0.125 1.66 (0.85 to 3.25) 0.140 1.39 (0.71 to 2.74) 0.338 
Quartile 3 (0.51-0.70) 22 / 1308 1.43 (0.72 to 2.84) 0.313 1.31 (0.65 to 2.62) 0.452 1.28 (0.64 to 2.56) 0.491 1.01 (0.50 to 2.05) 0.969 
Quartile 4 (0.71-13.23) 30 /1277 1.94 (1.01 to 3.75) 0.047 1.67 (0.86 to 3.27) 0.132 1.59 (0.81 to 3.12) 0.180 0.99 (0.48 to 2.02) 0.970 
p-value for trend   0.111  0.288  0.375  0.552 
Ischemic stroke 
Per 1 SD increase 70 / 5290 1.27 (1.00 to 1.61) 0.047 1.19 (0.93 to 1.53) 0.162 1.15 (0.90 to 1.49) 0.265 0.92 (0.70 to 1.21) 0.532 
Quartile 1 (0.02-0.35) 10 / 1323 ref  ref  ref  ref  
Quartile 2 (0.36-0.50) 19 / 1382 1.66 (0.77 to 3.58) 0.193 1.52 (0.71 to 3.30) 0.283 1.50 (0.69 to 3.24) 0.306 1.21 (0.55 to 2.64) 0.633 
Quartile 3 (0.51-0.70) 17 / 1308 1.36 (0.62 to 2.97) 0.447 1.21 (0.55 to 2.66) 0.634 1.17 (0.53 to 2.59) 0.691 0.89 (0.40 to 2.00) 0.786 
Quartile 4 (0.71-13.23) 24 / 1277 1.89 (0.90 to 3.96) 0.092 1.56 (0.73 to 3.32) 0.246 1.44 (0.67 to 3.09) 0.349 0.82 (0.36 to 1.85) 0.636 
p-value for trend   0.158  0.397  0.551  0.367 
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CI, confidence interval; HR, hazard ratio 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
Model 3: Model 2 plus triglycerides, body mass index, alcohol consumption, glucose, and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease 
Epidemiology Collaboration combined creatinine-cystatin C equation) 
Model 4: Model 3 plus loge high sensitivity C-reactive protein 
 28 
 
 Appendix 1. STROBE 2007 Statement—Checklist of items that should be included in reports of cohort studies 
 
 
 
Section/Topic Item 
# 
Recommendation Reported on page # 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract Page 1 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Page 4 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 4 
Methods  
Study design 4 Present key elements of study design early in the paper Study design and 
population 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Study design and 
population 
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Study design and 
population 
 
(b) For matched studies, give matching criteria and number of exposed and unexposed Not applicable 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Assessment of 
calprotectin and risk 
markers 
 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
Assessment of 
calprotectin and risk 
markers 
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Bias 9 Describe any efforts to address potential sources of bias Statistical analyses 
 
Study size 10 Explain how the study size was arrived at Statistical analyses 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and 
why 
Statistical analyses 
 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding Statistical analyses 
 
(b) Describe any methods used to examine subgroups and interactions Statistical analyses 
 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 
(e) Describe any sensitivity analyses Statistical analyses 
 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed 
eligible, included in the study, completing follow-up, and analysed 
Study design and 
population 
 
  (b) Give reasons for non-participation at each stage Study design and 
population 
 
  (c) Consider use of a flow diagram Study design and 
population 
 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential 
confounders 
Results; Tables 1-2  
  (b) Indicate number of participants with missing data for each variable of interest  
  (c) Summarise follow-up time (eg, average and total amount) Results 
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Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for and why they were included 
Results; Table 3 
  (b) Report category boundaries when continuous variables were categorized Results; Table 3 
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Results; Appendices 
2-4 
Discussion    
Key results 18 Summarise key results with reference to study objectives Discussion  
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information    
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which 
the present article is based 
Pages 15-16 
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Appendix 2. Prospective Associations of Plasma Calprotectin With Risk of Cardiovascular Disease, on Exclusion of First Two 
Years of Follow-up, People With History of Diabetes Mellitus, and Use of Lipid-lowering Medication 
 
Exclusions Events/ 
Total 
Model 1  Model 2  Model 3  Model 4  
  HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Cardiovascular disease 
First two years of follow-up 260 / 5097 1.31 (1.16 to 1.48) < 0.001 1.20 (1.05 to 1.36) 0.006 1.18 (1.04 to 1.35) 0.012 1.11 (0.96 to 1.28) 0.161 
People with a history of diabetes 297 / 5008 1.41 (1.26 to 1.58) < 0.001 1.27 (1.13 to 1.53) < 0.001 1.25 (1.11 to 1.42) < 0.001 1.16 (1.02 to 1.33) 0.026 
Use of lipid-lowering medication 318 / 5164 1.38 (1.24 to 1.54) < 0.001 1.25 (1.12 to 1.41) 0.001 1.24 (1.10 to 1.39) < 0.001 1.14 (1.00 to 1.29) 0.051 
 
CI, confidence interval; HR, hazard ratio; hazard ratios are reported per 1 standard deviation (SD) increase in loge calprotectin 
Model 1: Age and sex 
Model 2: Model 1 plus smoking status, history of diabetes, systolic blood pressure, total cholesterol, and high-density lipoprotein-cholesterol 
Model 3: Model 2 plus triglycerides, body mass index, alcohol consumption, glucose, and estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease 
Epidemiology Collaboration combined creatinine-cystatin C equation) 
Model 4: Model 3 plus loge high sensitivity C-reactive protein 
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Appendix 3. Hazard ratios for calprotectin and cardiovascular disease risk by several 
participant level characteristics 
 
Age at survey (years)
< 50
≥ 50
Sex
Males
Females
Alcohol consumption
Non-alcohol consumers
Alcohol consumers
Use of statins
No
Yes
History of diabetes
No
Yes
Smoking status
No
Yes
Fasting glucose (mmol/l)
< 5.0
≥ 5.0
Body mass index (kg/m2)
< 25.99
≥ 25.99
Systolic blood pressure (mmHg)
< 124
≥ 124
Total cholesterol (mmol/l)
< 5.41
≥ 5.41
HDL-cholesterol (mmol/l)
< 1.24
≥ 1.24
Estimated GFR (ml/min/1.73 m2)
< 94.35
≥ 94.35
hsC-reactive protein (mg/l)
< 1.30
≥ 1.30
Subgroup
2,362
2,928
2,530
2,760
1289
4,001
4,211
126
5,008
282
3,834
1,456
3,006
2,284
2,647
2,643
2,736
2,554
2,653
2,637
2,653
2,637
2,645
2,645
2,334
2,334
No. of participants
47
292
242
97
106
233
280
21
297
42
228
111
147
192
120
219
67
272
126
213
220
119
250
89
88
194
No. of CVD events
1.31 (1.00, 1.70)
1.28 (1.13, 1.45)
1.21 (1.07, 1.38)
1.37 (1.13, 1.68)
1.42 (1.17, 1.72)
1.19 (1.04, 1.36)
1.25 (1.11, 1.41)
1.30 (0.75, 2.25)
1.27 (1.13, 1.43)
1.16 (0.85, 1.57)
1.23 (1.07, 1.41)
1.32 (1.09, 1.60)
1.10 (0.93, 1.30)
1.40 (1.21, 1.62)
1.37 (1.15, 1.64)
1.19 (1.04, 1.37)
1.34 (1.04, 1.71)
1.26 (1.11, 1.42)
1.30 (1.09, 1.56)
1.23 (1.07, 1.41)
1.28 (1.12, 1.47)
1.25 (1.04, 1.52)
1.25 (1.10, 1.42)
1.28 (1.03, 1.59)
1.33 (1.04, 1.70)
1.20 (1.03, 1.40)
HR (95% CI)
.888
.307
.139
.896
.558
.542
.032
.228
.665
.612
.851
.853
.476
P-value*
1.5 .75 1.5 2.5
HR (95% CI) Per 1 SD increase in loge calprotectin
 
 
 
 
Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, systolic blood pressure, 
total cholesterol, and high-density lipoprotein-cholesterol; CI, confidence interval (bars); CVD, 
cardiovascular disease; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard 
ratio; hs, high sensitivity; SD, standard deviation; *, p-value for interaction; cut-offs used for fasting 
glucose, body mass index, systolic blood pressure, total cholesterol, HDL-cholesterol, estimated GFR, 
and hsC-reactive protein are median values. 
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Appendix 4. Direct Comparisons Within the PREVEND Study of Associations of 
Several  
Established and Emerging Cardiovascular Risk Markers With Risk of Cardiovascular 
Disease 
 
Risk marker Hazard Ratio (95% CI) p-value 
   
Mean age at time of survey (years) 2.15 (1.89 to 2.45) < 0.001 
Current smoker 1.79 (1.32 to 2.42) < 0.001 
Systolic blood pressure (mmHg) 1.37 (1.25 to 1.51) < 0.001 
History of diabetes 1.35 (0.97 to 1.88) 0.078 
Total cholesterol (mmol/l) 1.26 (1.13 to 1.40) < 0.001 
High-density lipoprotein cholesterol (mmol/l) 0.79 (0.70 to 0.90) < 0.001 
Triglycerides (mmol/l) 1.03 (0.94 to 1.12) 0.540 
High sensitivity C-reactive protein (mg/l) 1.30 (1.15 to 1.47) < 0.001 
 
Analyses are based on 5290 participants with 339 first-ever cardiovascular disease events. Hazard ratios were  
calculated per 1 standard deviation increment in measured level or as compared with the relevant reference 
category.  
Where appropriate, hazard ratios were adjusted for age, sex, plus smoking status, history of diabetes, systolic 
blood pressure,  
total cholesterol, and high-density lipoprotein-cholesterol 
 
 
 
 
 
 
 
 
